Live Breaking News & Updates on ஜய்துச் காடிலா சுகாதாரம்
Stay updated with breaking news from ஜய்துச் காடிலா சுகாதாரம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zydus Ahmedabad based Zydus Cadila Healthcare has started advance production of its under-trial DNA plasmid COVID-19 vaccine, even though it will be seeking an emergency use authorisation for the same in May or June, reports Livemint. The company is aiming to produce as many as 240 million doses per annum of its vaccine candidate ZyCoV-D . However, it should be noted that even though the company has begun producing the vaccine doses, the production right now is not meaningfully large , according to company s managing director Shravil Patel. Patel also shared that it aimed to produce 10 million doses a month starting June, with an in-house capacity of 120 million doses per annum. Meanwhile, the rest of the production will come from third-party producers. The company is already in talks with two other manufacturers and is also looking to partner with more manufacturers. ....
AHMEDABAD: Zydus Cadila Healthcare has started producing its potential Covid-19 vaccine for which it will seek emergency use authorisation in May or June, its managing director told Reuters, with an aim to make up to 240 million doses a year. Government officials have said they are eagerly waiting for Cadila to seek approval for ZyCoV-D soon, as a record rise in coronavirus infections have led to a public health disaster in the world s most populous country after China. We have just started producing doses, Sharvil Patel said in a Microsoft Teams interview on Friday. But it is not meaningfully large. He said the aim was to produce 10 million doses a month starting June, taking the in-house annual capacity to 120 million. The rest of the production, as required, will mainly come from third-party producers. ....
India's new COVID-19 cases hit record again amid vaccination push reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
NEW DELHI: Amid an unprecedented surge in fresh Covid-19 infections, multiple states, including Maharashtra, Gujarat and Delhi, have flagged a shortage of anti-viral drug Remdesivir. The shortage prompted the government to halt the export of the drug and Remdesivir active pharmaceutical ingredients (APIs) till the Covid spread is contained. As the country witnesses a ferocious resurgence of the virus, so has the demand for this medicine. Here are a few questions answered on the use of Remdesivir for Covid treatment and problems in the supply chain management. How did Remdesivir come into use? Remdesivir is an investigational antiviral drug to fight Sars-Cov 2, the virus that causes Covid-19. The US Food and Drug Administration (FDA) approved Gilead Sciences Inc’s antiviral therapy Remdesivir in October 2020, making it the first drug to obtain formal clearance for treating the coronavirus disease. ....
NEW DELHI: Amid an unprecedented surge in fresh Covid-19 infections, multiple states, including Maharashtra, Gujarat and Delhi, have flagged a shortage of anti-viral drug Remdesivir. The shortage prompted the government to halt the export of the drug and Remdesivir active pharmaceutical ingredients (APIs) till the Covid spread is contained. As the country witnesses a ferocious resurgence of the virus, so has the demand for this medicine. Here are a few questions answered on the use of Remdesivir for Covid treatment and problems in the supply chain management. How did Remdesivir come into use? Remdesivir is an investigational antiviral drug to fight Sars-Cov 2, the virus that causes Covid-19. The US Food and Drug Administration (FDA) approved Gilead Sciences Inc’s antiviral therapy Remdesivir in October 2020, making it the first drug to obtain formal clearance for treating the coronavirus disease. ....